179例甲状腺乳头状癌患者BRAF^(V600E)基因突变回顾性分析

Analysis of 179 BRAF^(V600E) mutation in papillary thyroid carcinoma patients

目的:检测BRAF^(V600E)基因突变在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中的发生情况,分析BRAF^(V600E)基因突变与临床参数、合并桥本氏甲状腺炎和结节性甲状腺肿的关系。方法:回顾性分析第四军医大学西京医院核医学科2015年6月1日至2016年5月31日所收治的甲状腺乳头状癌患者179例,由病理科检测BRAF^(V600E)突变情况。结果:179例患者病理结果显示BRAF^(V600E)基因突变率为61.5%。BRAF^(V600E)基因突变率与年龄和淋巴结转移个数相关(P<0.05),且随着年龄增大,突变的风险略有增高(OR=1.064)。合并结节性甲状腺肿的甲状腺乳头状癌患者48例,突变率75%;未合并结节性甲状腺肿的甲状腺乳头状癌患者131例,突变率56.5%,差异有统计学意义(P=0.024),且合并结节性甲状腺肿是BRAF^(V600E)基因突变的危险因素(OR=2.349)。结论:甲状腺乳头状癌患者的BRAF^(V600E)基因突变率与患者年龄、颈部淋巴结转移个数以及是否合并结节性甲状腺肿具有相关性。

Objective：To analyze the relations between BRAFV600E mutation and some pathological parameters in papillary thyroid carcinoma（ PTC）, and to investigate BRAFV600E mutation in PTC coexisting with Hashimoto thyroidi- tis or nodular goiter. Methods ：To retrospectively analyze data of 179 cases of post - operation PTC patients. Clinical datas were reviewed and evaluated by SPSS 21.0 statistical software package. Results：Among the 179 PTC patients, the presence of BRAFV600E mutation was 61.5%. There is a correlation between BRAFV600E mutation rate and age or numbers of lymph node metastasis （P 〈 0.05 respectively）. And age is a risk factor of BRAFV600E mutation（ OR = 1. 064）. The BRAFV600E mutation rate was higher in PTC patients coexisting with nodular goiter than patients with- out nodular goiter（ P = 0. 024 ）. And nodular goiter is also a risk factor（ OR = 2. 349 ）. Conclusion： The BRAFV600E mutation rates have correlation with age,numbers of lymph node metastasis and whether coexisting with nodular goiter.